

Influenza Session

Emmanuel (Chip) Walter, MD, MPH

Chair, Influenza Work Group

Advisory Committee on Immunization Practices

June 20, 2018

Influenza Work Group

ACIP Members

Emmanuel (Chip) Walter (Chair)

Robert Atmar

Ed Belongia

Hank Bernstein

Peter Szilagyi

***Ex Officio* Members**

Karin Bok (HHS)

David Cho (FDA)

Cynthia Nolletti (FDA)

Roshan Ramanathan (FDA)

Chris Roberts (NIH)

Consultants

Jeff Duchin

Wendy Keitel

Ruth Karron

Jamie Loehr

Liaison Representatives

Kevin Ault (ACOG)

Sarah Coles (AAFP)

Sarah Despres (Consumer representative)

Buddy Creech (PIDS)

Sandra Fryhofer (ACP; AMA)

Ian Gemmill (NACI)

Marie-Michèle Léger (AAPA)

Susan Lett (CSTE)

Flor Munoz (AAP)

Kathy Neuzil (IDSA)

William Schaffner (NFID)

Rob Schechter (AIM)

Ken Schmader (AGS)

Patsy Stinchfield (NAPNAP)

Rob Stirling (NACI)

Tamara Sheffield (AHIP)

Matthew Zahn (NACCHO)

Recap of Influenza Session, February 2018

- Presentation from GlaxoSmithKline of results of an RCT of Fluarix Quadrivalent for children 6 through 35 months of age
- U.S. influenza surveillance and vaccine effectiveness updates
- LAIV topics
 - Presentation from MedImmune of study of shedding and immunogenicity of LAIV4 containing a new H1N1pdm09-like virus
 - Presentation of combined U.S. individual-patient level analysis and systematic review of LAIV effectiveness
 - Vote for recommendation of use of LAIV4 for the 2018-19 season

Workgroup Activities Since February 2018

- Preview and discussion of
 - U.S. vaccine effectiveness estimates from CDC
 - U.S. Influenza Vaccine Effectiveness (U.S. Flu VE) Network
 - U.S. Hospitalized Influenza Vaccine Effectiveness Network (HAIVEN)
 - FDA study of relative effectiveness of cell-culture based vs. egg-based vaccines
 - 2017-18 influenza vaccine safety surveillance update
 - Seqirus study of quadrivalent adjuvanted inactivated influenza vaccine for young children
- Review and drafting of ACIP recommendations documents for the 2018-19 season

Maternal Influenza Sub-Working Group

- Formation of Maternal Influenza Immunization Sub-Working group
 - Purpose: provide advice on study of spontaneous abortion (SAB) following IIV
 - Met in April; reviewed protocol for the VSD-SAB study and provided recommendations for secondary analyses and sensitivity analyses

Agenda Overview

- **Vaccine Effectiveness Update (U.S. Flu VE Network and HAIVEN)**
 - Dr. Brendan Flannery (CDC/NCIRD/Influenza Division)
- **Relative Effectiveness of Cull-Cultures vs. Egg-Based Influenza Vaccines, 2017-18**
 - Dr. Yun Lu (FDA)
- **Influenza End-of-Season Update: 2017-2018 Influenza Vaccine Safety Monitoring**
 - Dr. Tom Shimabukuro (CDC/NCEZID/Immunization Safety Office)
- **Narcolepsy Following Adjuvanted Monovalent Pandemic H1N1 Influenza Vaccines: Results of the SOMNIA Study**
 - Dr. Tom Shimabukuro (CDC/NCEZID/Immunization Safety Office)
- **Adjuvanted Quadrivalent Influenza vaccine (aQIV) in young children**
 - Dr. Gregg Sylvester (Seqirus)
- **WG considerations; 2018-19 recommendations**
 - Dr. Lisa Grohskopf (CDC/NCIRD/Influenza Division)